Plain-English translation of NCT04803318 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study tests whether combining three medications — Trametinib, Everolimus, and Lenvatinib — can help shrink advanced cancers that have stopped responding to standard treatments. These three drugs work in different ways to attack cancer cells and slow their growth. Researchers will measure whether the medication helps control the cancer and how well patients tolerate it.
Many patients with advanced cancers that have returned or resisted standard treatments have very few options left. This trial explores whether combining three different medications that target cancer in complementary ways might be more effective than any single drug alone.
You likely qualify if…
You likely don't qualify if…
You would take the three medications by mouth as directed by the research team. The doctors would measure your tumor size at regular intervals to see how well the treatment is working. You'll likely have several visits for blood tests, imaging scans, and check-ins to monitor how you're responding and watch for any side effects.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Enrollment target
~100 participants
Started
January 2021
Primary completion
January 2029
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.